- Home
- GSL vs ABVX Comparison
GSL vs ABVX Comparison
Compare GSL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- ABVX
- Stock Information
- Founded
- GSL 2007
- ABVX 2013
- Country
- GSL Greece
- ABVX France
- Employees
- GSL N/A
- ABVX N/A
- Industry
- GSL Marine Transportation
- ABVX
- Sector
- GSL Consumer Discretionary
- ABVX
- Exchange
- GSL Nasdaq
- ABVX Nasdaq
- Market Cap
- GSL 766.6M
- ABVX 722.3M
- IPO Year
- GSL 2006
- ABVX N/A
- Fundamental
- Price
- GSL $22.68
- ABVX $8.08
- Analyst Decision
- GSL Strong Buy
- ABVX Strong Buy
- Analyst Count
- GSL 1
- ABVX 7
- Target Price
- GSL $29.00
- ABVX $37.86
- AVG Volume (30 Days)
- GSL 320.3K
- ABVX 162.8K
- Earning Date
- GSL 03-03-2025
- ABVX 03-24-2025
- Dividend Yield
- GSL 7.94%
- ABVX N/A
- EPS Growth
- GSL 7.30
- ABVX N/A
- EPS
- GSL 8.96
- ABVX N/A
- Revenue
- GSL $701,476,000.00
- ABVX $9,676,417.00
- Revenue This Year
- GSL $6.45
- ABVX $31.67
- Revenue Next Year
- GSL N/A
- ABVX $759.77
- P/E Ratio
- GSL $2.53
- ABVX N/A
- Revenue Growth
- GSL 8.60
- ABVX 100.87
- 52 Week Low
- GSL $18.75
- ABVX $5.50
- 52 Week High
- GSL $30.32
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- GSL 59.05
- ABVX 75.42
- Support Level
- GSL $21.46
- ABVX $5.88
- Resistance Level
- GSL $23.30
- ABVX $7.57
- Average True Range (ATR)
- GSL 0.49
- ABVX 0.46
- MACD
- GSL 0.14
- ABVX 0.24
- Stochastic Oscillator
- GSL 74.80
- ABVX 97.68
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.